Annual Congress Berlin 2001

Saturday, 22.09.2001
Sunday, 23.09.2001
Monday, 24.09.2001
Tuesday, 25.09.2001
Wednesday, 26.09.2001

Citations should be made in the following way: Authors. Title. Eur Respir J 2004; 18: Suppl. 33, abstract number.


Material from 2001:
  • 3025  Abstracts
Material from 2001:  Show

New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE

Poster Discussion
Chairs: K. F. Rabe (Leiden, The Netherlands), J. C. Kips (Ghent, Belgium)
Production of matrix metalloprotease-9 (MMP-9) by alveolar macrophages (AMs) from smokers: effect of corticosteroids and phosphodiesterase inhibition
N. Roche, S. Lim, B. G. Oliver, K. F. Chung (London, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions
G. P. Downey, E. Malus, V. Cherapanov, A. Arora, C. Loeve (Toronto, Canada)
Congress or journal article abstract
Congress or journal article abstract
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients
M. Ouagued, C. Martin-Chouly, C. Leportier, C. Belleguic, P. Delaval, V. Lagente, C. Danzin, C. Bertrand, M. P. Pruniaux (Fresnes, Rennes, France)
Congress or journal article abstract
Congress or journal article abstract
First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients
D. C. Grootendorst, S. A. Gauw, J. Kelly, R. D. Murdoch, P. J. Sterk, K. F. Rabe (Leiden, The Netherlands; Harlow, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
NIK-616, a new type of selective phosphodiesteraseIV(PDE IV) inhibitor with reduced emetic activity
K. Yamana, N. Suzuki, T. Ohtani, T. Machida, S. Ina (Omiya, Saitama, Japan)
Congress or journal article abstract
Congress or journal article abstract
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit
H. Jones, W. Paul, C. Page (London, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
Inhibition by roflumilast of airway hyperresponsiveness to adenosine and pulmonary inflammation in allergen challenged Brown-Norway rats
L. Wollin, J. Barsig, D. S. Bundschuh, D. Marx, R. Beume (Konstanz, Germany)
Congress or journal article abstract
Congress or journal article abstract
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilast
D. S. Bundschuh, J. Barsig, R. Beume, M. Eltze, C. Schudt, L. Wollin, A. Hatzelmann (Konstanz, Germany)
Congress or journal article abstract
Congress or journal article abstract
Efficacy of the PDE4 inhibitor, BAY 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig
M. F. Fitzgerald, D. Spicer, H. Lisle, N. Bowyer, R. G. Sturton, D. Minshall, B. Meshi, D. Ionescu, M. T. Shrad, J. C. Hogg (Stoke Poges, United Kingdom; Vancouver, Canada)
Congress or journal article abstract
Congress or journal article abstract
A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models
M. F. Fitzgerald, B. A. Briggs, A. M. Thompson, D. F. Edwards, R. G. Sturton (Stoke Poges, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004
R. G. Sturton, N. M. Butt, S. P. Palfai, S. R. Tudhope, T. S. Abram, R. Fischer, R. Henning, G. Braunlich, M. Es-Sayed (Stoke Poges, United Kingdom; Elberfield, Germany)
Congress or journal article abstract
Congress or journal article abstract
The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models
N. Fitch, M. S. Freeman, R. G. Sturton, P. Harris, D. Lindell, R. Gundel (Berkeley, United States Of America; Stoke Poges, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation
M. F. Fitzgerald, D. Spicer, E. Clark, N. Bowyer (Stoke Poges, United Kingdom)
Congress or journal article abstract
Congress or journal article abstract
Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma
G. Hanf, O. Noga, A. O'Connor, G. Kunkel (Berlin, Germany)
Congress or journal article abstract
Congress or journal article abstract
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma
O. Noga, G. Hanf, E. Kirchhof, C. Buettner, G. Kunkel (Berlin, Germany)
Congress or journal article abstract
Congress or journal article abstract
Omalizumab, a novel therapy for severe allergic asthma

Congress or journal article abstract
Congress or journal article abstract
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma

Congress or journal article abstract
Congress or journal article abstract
Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma

Congress or journal article abstract
Congress or journal article abstract
Omalizumab in the treatment of perennial allergic rhinitis
T. Casale, P. Chervinsky, W. Busse, A. Nayak, I. Tripathy, A. Fowler Taylor, N. Gupta, H. Shen (Omaha, North Dartmouth, Madison, Normal, Rolla, East Hanover, United States Of America)
Congress or journal article abstract
Congress or journal article abstract